SCHEMBL6178247

SCHEMBL6178247

CC(C)(C)CCOCOCCC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.34
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20414616 0.89 HRH3 (0.31) HRH3
SCHEMBL133695 0.86 HRH3 (0.41) HRH3
SCHEMBL12711202 0.85 HRH3 (0.32) HRH3
SCHEMBL13488795 0.84 TSHR (0.41) HRH3ALDH1A1
SCHEMBL20414617 0.83 HRH3 (0.31) HRH3
SCHEMBL19164021 0.83 HRH3 (0.39) HRH3
SCHEMBL26254694 0.83 HRH3 (0.39) HRH3
SCHEMBL1753765 0.83 HRH3 (0.39) HRH3
SCHEMBL15223081 0.83 HRH3 (0.39) HRH3
SCHEMBL26254285 0.83 HRH3 (0.39) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11292853-B2 Methods and compositions for curing a surface of an uncured polysulfide rubber THE BOEING COMPANY (US) 2022-04-05 US disclosed
US-20200190226-A1 METHODS AND COMPOSITIONS FOR CURING A SURFACE OF AN UNCURED POLYSULFIDE RUBBER THE BOEING COMPANY 2020-06-18 US disclosed
US-9822134-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-11-21 US disclosed
US-9556210-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-01-31 US disclosed
US-20160176903-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2016-06-23 US disclosed
US-20160039850-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2016-02-11 US disclosed
US-9156865-B2 System for delivering therapeutic agents into living cells and cells nuclei DELIVERSIR LTD (IL) 2015-10-13 US disclosed
US-20130137755-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SEGEV LABORATORIES LIMITED (IL) 2013-05-30 US disclosed
US-20100036136-A1 Maleimide Containing Ester and Sulfide Functionalities HENKEL AG & CO. KGAA (DE) 2010-02-11 US disclosed
EP-0945445-B9 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARM CO LTD (JP) 2005-12-28 EP disclosed
EP-0945445-B1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARM CO LTD (JP) 2003-09-03 EP disclosed
US-6239131-B1 WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. ZERIA PHARMACEUTICAL CO., LTD. (JP) 2001-05-29 US disclosed
EP-0945445-A1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039850-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 HRH3 2968/4885ALDH1A1 4566/4885
US-20100036136-A1 Maleimide Containing Ester and Sulfide Functionalities EPCAM, ILK, TST HRH3 4115/4885ALDH1A1 1531/4885
US-20130137755-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 HRH3 2968/4885ALDH1A1 4566/4885
US-20160176903-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 HRH3 2968/4885ALDH1A1 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.